JP2011510654A5 - - Google Patents

Download PDF

Info

Publication number
JP2011510654A5
JP2011510654A5 JP2010545017A JP2010545017A JP2011510654A5 JP 2011510654 A5 JP2011510654 A5 JP 2011510654A5 JP 2010545017 A JP2010545017 A JP 2010545017A JP 2010545017 A JP2010545017 A JP 2010545017A JP 2011510654 A5 JP2011510654 A5 JP 2011510654A5
Authority
JP
Japan
Prior art keywords
antibody
hybridoma
antigen
fragment
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010545017A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011510654A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/000562 external-priority patent/WO2009105150A2/en
Publication of JP2011510654A publication Critical patent/JP2011510654A/ja
Publication of JP2011510654A5 publication Critical patent/JP2011510654A5/ja
Pending legal-status Critical Current

Links

JP2010545017A 2008-01-28 2009-01-28 有用な抗体を発現する雑種細胞の作成方法 Pending JP2011510654A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6258408P 2008-01-28 2008-01-28
PCT/US2009/000562 WO2009105150A2 (en) 2008-01-28 2009-01-28 Method of making hybrid cells that express useful antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015009809A Division JP5923186B2 (ja) 2008-01-28 2015-01-21 有用な抗体を発現する雑種細胞の作成方法

Publications (2)

Publication Number Publication Date
JP2011510654A JP2011510654A (ja) 2011-04-07
JP2011510654A5 true JP2011510654A5 (enExample) 2012-03-15

Family

ID=40986086

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010545017A Pending JP2011510654A (ja) 2008-01-28 2009-01-28 有用な抗体を発現する雑種細胞の作成方法
JP2015009809A Active JP5923186B2 (ja) 2008-01-28 2015-01-21 有用な抗体を発現する雑種細胞の作成方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015009809A Active JP5923186B2 (ja) 2008-01-28 2015-01-21 有用な抗体を発現する雑種細胞の作成方法

Country Status (4)

Country Link
US (1) US8999707B2 (enExample)
EP (1) EP2242836B1 (enExample)
JP (2) JP2011510654A (enExample)
WO (1) WO2009105150A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563874B2 (en) 1998-08-31 2009-07-21 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
EP2134749B1 (en) 2007-03-22 2013-11-06 The Regents of the University of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
WO2009131605A2 (en) * 2008-01-28 2009-10-29 Thomas Jefferson University Fusion partner cell line for preparation of hybrid cells expressing human antibodies
WO2010003529A1 (en) * 2008-06-16 2010-01-14 University Of Zurich Method of providing immunoglobulin secreting b lymphocytes and human antibodies
US9000131B2 (en) 2008-07-31 2015-04-07 The Regents Of The University Of California Antibodies that neutralize botulinum neurotoxins
US8821879B2 (en) 2009-09-04 2014-09-02 Xoma Technology Ltd. Anti-botulism antibody coformulations
EP2473191B1 (en) * 2009-09-04 2017-08-23 XOMA Technology Ltd. Antibody coformulations
DK2400298T3 (da) * 2010-05-28 2013-09-02 Hoffmann La Roche Enkelt B-celle-dyrkningsfremgangsmåde og specifik antistoffremstilling
WO2012047427A2 (en) 2010-08-31 2012-04-12 The Regents Of The University Of California Antibodies for botulinum neurotoxins
PT2646466T (pt) * 2010-12-02 2017-06-07 Aimm Therapeutics Bv Meios e métodos para produzir anticorpos de alta afinidade
WO2013000982A1 (en) 2011-06-27 2013-01-03 Vivalis Method for screening cells
CN103946236B (zh) * 2011-11-23 2018-02-16 弗·哈夫曼-拉罗切有限公司 表达cd40l的哺乳动物细胞及其用途
US10017739B2 (en) 2012-09-06 2018-07-10 Duke University Methods of expanding and assessing B cells and using expanded B cells to treat disease
WO2014138733A2 (en) * 2013-03-08 2014-09-12 Dessain Scott K Compositions and methods for making human antibodies
US20160014600A1 (en) * 2014-07-10 2016-01-14 Bank Of America Corporation Identification of Potential Improper Transaction
US20160253708A1 (en) * 2015-02-26 2016-09-01 Dropbox, Inc. Method and system for efficiently serving upsell content based on complex user archetypes
AU2017218415B2 (en) 2016-02-10 2024-05-02 Rutgers, The State University Of New Jersey Novel anti-LAM and anti-PIM6/LAM monoclonal antibodies for diagnosis and treatment of mycobacterium tuberculosis infections
WO2018112407A1 (en) 2016-12-15 2018-06-21 Duke University Antibodies and methods for depleting regulatory b10 cells and use in combination with immune checkpoint inhibitors
SG11202103411RA (en) 2018-10-02 2021-04-29 Immunome Inc Antibodies targeting epn1
WO2022150809A1 (en) 2021-01-05 2022-07-14 Immunome, Inc. Antibody cocktail against sars-cov-2 spike protein
CN114350606A (zh) * 2022-01-05 2022-04-15 上海药明生物医药有限公司 一种富集大鼠浆细胞及建立浆细胞杂交瘤的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3150991B2 (ja) * 1991-04-10 2001-03-26 協和醗酵工業株式会社 ハイブリドーマの製造法
US6541225B1 (en) 2000-01-26 2003-04-01 Raven Biotechnologies, Inc. Methods and compositions for generating human monoclonal antibodies
WO2003052082A2 (en) 2001-12-18 2003-06-26 Whitehead Institute For Biomedical Research Fusion partner cells and uses thereof
EP1692276B1 (en) 2003-11-19 2010-07-21 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Method of inducing memory b cell development and terminal differentiation
ATE505535T1 (de) 2005-08-23 2011-04-15 Iq Corp Verfahren zur herstellung stabiler b-lymphozyten
WO2009131605A2 (en) * 2008-01-28 2009-10-29 Thomas Jefferson University Fusion partner cell line for preparation of hybrid cells expressing human antibodies

Similar Documents

Publication Publication Date Title
JP2011510654A5 (enExample)
JP2022177090A5 (enExample)
RU2020120539A (ru) Композиции для ингибирования masp-2-зависимой активации комплемента
JP2011526785A5 (enExample)
HRP20191697T1 (hr) Vezujuće molekule za bcma i cd3
JP2020534830A5 (enExample)
RU2012142230A (ru) Антитела против csf-1r человека и их применение
RU2012147638A (ru) Антитела против растворимого st-2 человека и способы анализа
HRP20131215T1 (hr) Antagonistiäśka humana monoklonska protutijela specifiäśna za humane slabe epitope
JP2020504101A5 (enExample)
IL273196B1 (en) Claudin 6 antibodies and methods of cancer treatment
JP2015508056A5 (enExample)
RU2012142231A (ru) Антитела против csf-1r человека и их применение
RU2008129111A (ru) Антитела к ox40l и способы их применения
RU2014103784A (ru) Антитело, блокирующее agr2, и его применение
NZ603226A (en) Anti-c5a antibodies and methods for using the antibodies
KR20210100654A (ko) Cd3 항체 및 그의 약제학적 용도
RU2009126766A (ru) Антитела человека к дельта-подобному лиганду-4 человека
RU2013142600A (ru) Белки, связывающие специфический мембранный антиген простаты, и соответствующие композиции и способы
JP2011527899A5 (enExample)
NZ597067A (en) Monoclonal antibodies expressed by ATCC PTA-4621 for the treatment of cancer
RU2009111884A (ru) Последовательности вариабельных областей моноклональных антител против il-31 и способы использования
JP2012523848A5 (enExample)
FI3561057T3 (fi) Anti-cd3-vasta-aine ja vasta-ainetta sisältäviä molekyylejä
RU2012137380A (ru) Моноклональные антитела к cd44, предназначенные для применения при лечении плоскоклеточной карциномы головы и шеи